Abstract
The field of angiogenesis modulation is at a major crossroad. Tremendous advancement in basic science in this field is providing several novel targets and strategies, which is in contrast to the limited clinical support, resulting in a large gap between experimental and clinical data. This gap might be helped through the selection of clinically relevant surrogate biomarkers that correlate with clinical outcome. Additionally, in the design of clinical trials, hard endpoints (such as mortality, quality of life, and cost-effectiveness of the anti-angiogenesis strategy) in addition to surrogate biomarkers and non-invasive imaging of tumour and its micro-vascular environment should be used. Furthermore, adjunct therapies that maximize the efficacy and minimize complications associated with cancer and its current standard therapy should also be used.
| Original language | English (US) |
|---|---|
| Title of host publication | Angiogenesis Assays |
| Subtitle of host publication | A Critical Appraisal of Current Techniques |
| Publisher | John Wiley & Sons, Ltd |
| Pages | 341-359 |
| Number of pages | 19 |
| ISBN (Print) | 0470016000, 9780470016008 |
| DOIs | |
| State | Published - Sep 27 2007 |
| Externally published | Yes |
Keywords
- Angiogenesis modulation
- Anti-angiogenesis
- Dynamic contrast enhanced MRI (DCE-MRI)
- Microvessel density
- Monitoring clinical trials
- Platelets and angiogenesis
- Tumour angiogenesis target in anticancer therapy
- Tumour micro-environmental factors
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology